In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Novartis divests Sandoz's US generics businesses to Aurobindo for up to $1bn

Executive Summary

Aurobindo Pharma Ltd.'s Aurobindo Pharma USA Inc. agreed to buy certain portions of Sandoz International GMBH's US Sandoz's US generic dermatology and US generic oral solids businesses, which parent Novartis AG is divesting.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register